British antiaging biotech startup Five Alarm Bio (FAB) recently closed a seed funding round from investors including Cambridge Angels, Meltwind, o2h Ventures and SyndicateRoom, among others. The funding follows a $450,000 Biomedical Catalyst grant from Innovate UK, awarded to FAB early last year to develop its technology as a treatment for chronic wounds.
Based on breakthrough advances made by its founder Dr William Bains in understanding of how age-associated chemical damage accumulates in cells and tissues, FAB is developing a small molecule approach aimed at boosting our defences as we age, to ultimately extend the healthy lifespan of our bodies.
A key player involved in orchestrating the round was o2h Ventures. The Cambridge-based investment firm specializes in biotech and FAB is the first longevity-specific investment it has made.
To read more, please visit – longevity.technology/news/longevity-investment-good-companies-will-continue-to-get-funded/